The Asia Pacific biosimilar insulin glargine and lispro market size was valued at USD 1864.8 million in 2023, driven by rising prevalence of diabetes across the region. The market size is anticipated to grow at a CAGR of 14.3% during the forecast period of 2024-2032 to achieve a value of USD 6210.9 million by 2032. Biosimilar Insulin Glargine and Lispro: Introduction Biosimilar...